• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Gunn Neil converted options into 23,077 shares, increasing direct ownership by 82% to 51,177 units (SEC Form 4)

    6/3/26 7:45:50 PM ET
    $NEO
    Precision Instruments
    Health Care
    Get the next $NEO alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Gunn Neil

    (Last)(First)(Middle)
    9490 NEOGENOMICS WAY

    (Street)
    FORT MYERS FLORIDA 33912

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    NEOGENOMICS INC [ NEO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/01/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock06/01/2026M23,077(1)A$051,177.31D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Unit$006/01/2026M23,07706/01/2026 (2)Common Stock23,077$00D
    Stock Option (Right to Buy)$10.5206/01/2026A11,06906/01/202706/01/2036Common Stock11,069$011,069D
    Restricted Stock Unit$006/01/2026A15,97006/01/2027 (2)Common Stock15,970$015,970D
    Stock Option (Right to Buy)$14.8208/10/202408/10/2033Common Stock8,3538,353D
    Stock Option (Right to Buy)$13.7106/01/202506/01/2034Common Stock8,6728,672D
    Stock Option (Right to Buy)$7.2806/01/202606/01/2035Common Stock16,10716,107D
    Explanation of Responses:
    1. Reflects the release of restricted stock units that were previously reported on a Form 4.
    2. Once vested, the shares of common stock are not subject to expiration.
    Remarks:
    /s/ Ali Olivo, Attorney-in-Fact06/03/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $NEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEO

    DatePrice TargetRatingAnalyst
    4/29/2026$25.00Market Perform → Outperform
    Leerink Partners
    7/30/2025Buy → Neutral
    BTIG Research
    7/29/2025Outperform → Mkt Perform
    William Blair
    5/15/2025Neutral
    Guggenheim
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    1/13/2025Buy → Hold
    The Benchmark Company
    12/10/2024$22.00Buy
    Jefferies
    5/1/2024$26.00Buy
    Craig Hallum
    More analyst ratings

    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Starrett Carolyn S

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    6/25/26 4:09:33 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 3 filed by new insider Starrett Carolyn S

    3 - NEOGENOMICS INC (0001077183) (Issuer)

    6/25/26 4:08:55 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Tetrault Lynn A. sold $58,908 worth of shares (5,307 units at $11.10), decreasing direct ownership by 6% to 86,115 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    6/17/26 4:07:59 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

    NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice ("DOJ") on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services ("OIG") resolving an investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Collaboration Initiative program. The Company self-disclosed the matter to the OIG in November 2021. As the DOJ acknowledged in the settlement agreement, the Company cooperated with the governm

    7/20/26 5:23:00 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

    Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca’s recently approved targeted therapy TRUQAP® (capivasertib).1 PTEN IHC CDx extends the company's reach into

    7/9/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (9

    7/7/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NeoGenomics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded NeoGenomics from Market Perform to Outperform and set a new price target of $25.00

    4/29/26 8:00:47 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by BTIG Research

    BTIG Research downgraded NeoGenomics from Buy to Neutral

    7/30/25 7:31:39 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by William Blair

    William Blair downgraded NeoGenomics from Outperform to Mkt Perform

    7/29/25 12:56:34 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    SEC Filings

    View All

    NeoGenomics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    7/20/26 5:27:16 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    6/25/26 7:10:14 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    6/22/26 5:17:36 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Leadership Updates

    Live Leadership Updates

    View All

    NeoGenomics Appoints Carolyn Starrett to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies, and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years, from 2016 to 2026, at Flatiron Health, serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory

    6/25/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

    – Anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million; full-year 2025 revenue of $727 million – – Announces Chief Financial Officer transition – NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, Neo

    1/12/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Financials

    Live finance-specific insights

    View All

    NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (9

    7/7/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports First Quarter 2026 Results

    First quarter total revenue increased 11% YoY to $187 million; Clinical revenue grew 14%, including NGS growth of 26%; Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first quarter results for the period ended March 31, 2026. First Quarter 2026 Financial Highlights As Compared To First Quarter 2025   Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%   Net loss decreased 34% to $17 million

    4/28/26 4:05:00 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls after market close to allow time for follow-up discussions before the next trading day. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast

    4/7/26 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G filed by NeoGenomics Inc.

    SC 13G - NEOGENOMICS INC (0001077183) (Subject)

    2/14/24 10:04:34 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    2/13/24 5:09:41 PM ET
    $NEO
    Precision Instruments
    Health Care